N-((4-chlorophenyl)(2-methyl-1H-indol-3-yl)methyl)aniline  | 1378490-40-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-((4-chlorophenyl)(2-methyl-1H-indol-3-yl)methyl)aniline
• 英文别名: N-((4-chlorophenyl)(2-methyl-1H-indol-3-yl)methyl)aniline；N-[(4-chlorophenyl)-(2-methyl-1H-indol-3-yl)methyl]aniline
• CAS: 1378490-40-4
• 化学式: C₂₂H₁₉ClN₂
• 分子量: 346.859
• InChiKey: XECLBYVJWQYBLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-甲基吲哚 、 4-氯苯甲醛 、 苯胺 在 正癸酸 作用下， 以 甲苯 为溶剂， 反应 1.0h， 以36%的产率得到N-((4-chlorophenyl)(2-methyl-1H-indol-3-yl)methyl)aniline 
  参考文献：
  名称：

  Discovery of the First Irreversible Small Molecule Inhibitors of the Interaction between the Vitamin D Receptor and Coactivators

  摘要：

  The vitamin D receptor (VDR) is a nuclear hormone receptor that regulates cell proliferation, cell differentiation, and calcium homeostasis. The receptor is activated by vitamin D analogues that induce the disruption of VDR-corepressor binding and promote VDR-coactivator interactions. The interactions between VDR and coregulators are essential for VDR-mediated transcription. Small molecule inhibition of VDR-coregulator binding represents an alternative method to the traditional ligand-based approach in order to modulate the expression of VDR target genes. A high throughput fluorescence polarization screen that quantifies the inhibition of binding between VDR and a fluorescently labeled steroid receptor coactivator 2 peptide was applied to discover the new small molecule VDR-coactivator inhibitors, 3-indolylmethanamines. Structure-activity relationship studies with 3-indolylmethanamine analogues were used to determine their mode of VDR-binding and to produce the first VDR-selective and irreversible VDR-coactivator inhibitors with the ability to regulate the transcription of the human VDR target gene TRPV6.

  DOI：

  10.1021/jm300460c

文献信息

• Vitamin D receptor-coregulator inhibitors
  申请人：UWM Research Foundation, Inc.

  公开号：US10093653B2

  公开（公告）日：2018-10-09

  Described herein are compounds, pharmaceutical compositions and methods for inhibiting the expression of a vitamin D receptor target gene, inhibiting interactions between the vitamin D receptor and at least one vitamin D receptor coactivator, for treating cancer in a subject, and for inhibiting angiogenesis in a subject.

  本文描述了用于抑制维生素 D 受体靶基因表达、抑制维生素 D 受体与至少一种维生素 D 受体辅激活剂之间相互作用、治疗受试者癌症以及抑制受试者血管生成的化合物、药物组合物和方法。
• BRANCHED DISCRETTE PEG CONSTRUCTS
  申请人：Quanta Biodesign, Ltd.

  公开号：EP2750681A1

  公开（公告）日：2014-07-09
• VITAMIN D RECEPTOR-COREGULATOR INHIBITORS
  申请人：Arnold Alexander E.

  公开号：US20140194472A1

  公开（公告）日：2014-07-10

  Described herein are compounds, pharmaceutical compositions and methods for inhibiting the expression of a vitamin D receptor target gene, inhibiting interactions between the vitamin D receptor and at least one vitamin D receptor coactivator, for treating cancer in a subject, and for inhibiting angiogenesis in a subject.
• US9416104B2
  申请人：——

  公开号：US9416104B2

  公开（公告）日：2016-08-16
• [EN] VITAMIN D RECEPTOR - COREGULATOR INHIBITORS<br/>[FR] INHIBITEURS DE RÉCEPTEUR DE VITAMINE D - CO-RÉGULATEUR
  申请人：UWM RES FOUNDATION INC

  公开号：WO2013032960A2

  公开（公告）日：2013-03-07

  Described herein are compounds, pharmaceutical compositions and methods for inhibiting the expression of a vitamin D receptor target gene, inhibiting interactions between the vitamin D receptor and at least one vitamin D receptor coactivator, for treating cancer in a subject, and for inhibiting angiogenesis in a subject.